MicroRNA-145 inhibits migration and invasion via inhibition of fascin 1 protein expression in non-small-cell lung cancer cells
Authors: Weibin Zhou
Haijun Wu
Yingying Zhang
Xucheng Yang
Zhenzhen Liu
Journal: Molecular Medicine Reports (2015)
Discipline: CLINICAL MEDICINE
Keywords: MicroRNA-145; miR-145; suppressor; cancer; non-small-cell lung cancer
Affiliations: Department of Oncology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China., Department of Orthopedics, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China.

Abstract:  MicroRNA (miR)-145 has been shown to act as a suppressor in numerous cancer types, including non-small-cell lung cancer (NSCLC). Fascin 1 (FSCN1), an actin bundling protein, has been implicated in NSCLC. However, the detailed role of miR-145 as well as the association between miR-145 and FSCN1 in the regulation of migration and invasion in NSCLC cells has remained elusive. The present study revealed that miR-145 was downregulated and FSCN1 was upregulated in NSCLC tissues and cell lines. Further investigation showed that overexpression of miR-145 markedly inhibited the protein expression of FSCN1, while knockdown of miR-145 upregulated the protein (but not mRNA) levels of FSCN1 in the NSCLC cell line H129. Moreover, a luciferase reporter assay indicated that FSCN1 is a direct target of miR-145 in NSCLC H129 cells. Furthermore, overexpression of miR-145 markedly inhibited the migration and invasion of NSCLC cells, similar to the effect of small interfering RNA-mediated FSCN1 inhibition in H129 cells. In addition, the inhibitory effect of miR-145 overexpression on migration and invasion was reversed by FSCN1 upregulation in H129 cells. These findings suggested that miR-145 has an inhibitory effect on the migration and invasion in NSCLC cells, at least in part through suppressing the protein expression of its target FSCN1. Therefore, miR-145/FSCN1 may be used as a potential target for the treatment of NSCLC. 

Retracted: Yes

PubPeer comments:
 Fig 4.  (A) A Transwell assay was performed to examine the migratory capacity of H129 cells transfected with miR-145 mimics or FSCN1 siRNA, or co-transfected with miR-145 mimics and FSCN1 plasmid, respectively. H129 cells without any transfection were used as a control.... (B) A Transwell assay was performed to examine the invasive capacity of H129 cells transfected with miR-145 mimics or FSCN1 siRNA, or co-transfected with miR-145 mimics and FSCN1 plasmid, respectively . ![file] These are versatile panels, appearing in literally dozens of papers by unrelated teams of researchers. Figs 4 and 7 of [Aili, Chen Zhang (2016)] .  Transwell assay was performed to determine the invasive capacity of JJ012 chondrosarcoma cells treated with 5-Aza+PBA, or transfected with NC or miR-10b mimics, respectively ;  A Transwell assay was performed to determine the invasive capacity of JJ012 chondrosarcoma cells transfected with miR-10b mimics, or co-transfected with miR-10b mimics and BDNF plasmid respectively. ![file] Fig 3 C D of [Zhang et al (2016)] .  Transwell assay were performed to examine the migratory and invasive capacities of Saos-2 and U2OS cells transfected with miR-205 mimic or miR-negative control (NC) mimic , and Fig 7C D,  Transwell assay were performed to examine cell migration and invasion of MG63 or U2OS cells transfected with miR-205 mimic, or co-transfected with miR-205 mimic and RUNX2 plasmid . ![] Also *[above]* Fig 4C from [Lai, Chen Li (2015)] .  a Transwell assay were performed to examine the cell proliferation of AGS cells transfected with miR-133a mimics, miR-133a inhibitor, or co-transfected with miR-133a mimics and FSCN1 plasmid. Control: AGS cells without any transfection. *[below]* Figs 3(B), 6(B) from [Shi et al (2015)] .  Transwell assay was performed to determine the invasive capacity of the Saos-2 and U-2 OS cells transfected with NC scramble miRNA or miR-204 mimics, respectively. Control, Saos-2 and U-2 OS cells without any transfection ...  Transwell assay was performed to determine the invasive capacity of the Saos-2 and U-2 OS cells transfected with Sirt1 siRNA or co-transfected with miR-204 mimics and the Sirt1 plasmid, respectively. Control, Saos-2 and U-2 OS cells without any transfection . ![file] , 
 Retracted [13 August 2021] . -------------------------- Following the publication of this paper, it was drawn to the Editorsu2019 attention by a concerned reader that certain of the Transwell cell migration data shown in Fig. 4 were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to *Molecular Medicine Reports*, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive any reply. The Editor apologizes to the readership for any inconvenience caused. ,